spacer
home > epc > spring 2009 > under close examination - the rules of competition
PUBLICATIONS
European Pharmaceutical Contractor

Under Close Examination - The Rules of Competition

In January 2008, the European Commission launched a sector inquiry into EU pharmaceuticals markets under the EC competition rules because information relating to innovative and generic medicines suggested that competition may be restricted or distorted. The motivating force behind the inquiry is the Commission’s perception that there is a decline in innovation in the sector when measured by the number of novel medicines reaching the market, and (not necessarily connected) that there are instances of delayed market entry of generic medicines as compared to what might be expected.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Gerry Kamstra is a Life Sciences lawyer, particularly recognised as a specialist in IP and commercial agreements, and in IP litigation for clients in the life sciences sector. He also leads Bird & Bird’s International Life Sciences Group. He obtained a PhD in physiology before qualifying as a lawyer and has advised and represented numerous clients in the life sciences sector, from start-ups to multinationals. Gerry is a member of the Intellectual Property Advisory Committee of the BioIndustry Association.

spacer
Gerry Kamstra
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

Considerations for Choosing the Right Wearable Drug Delivery System

West Pharmaceutical Services, Inc.

For patients with chronic conditions, the use of injectable biologic therapies is on the rise. Biologics, while providing considerable therapeutic benefit, can also present several challenges for both drug manufacturers and patients. In particular, many biologics are highly viscous and others require large doses to be injected slowly over time. This can make it difficult to deliver a consistent dose every time, potentially impacting medication adherence.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement